Incyte (NASDAQ:INCY) is working with the FDA to initiate
a Phase 3 clinical trial, RUXCOVID, to evaluate the efficacy and safety
of ruxolitinib (Jakafi) plus standard-of-care (SoC), compared to SoC
therapy alone, in patients with COVID-19 associated cytokine storm.
Additionally, the company intends to launch a
separate Expanded Access Program in the U.S. to allow eligible patients
with COVID-19 associated cytokine storm to receive ruxolitinib.
https://seekingalpha.com/news/3558122-incyte-to-test-jakafi-in-covidminus-19-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.